122 related articles for article (PubMed ID: 27648723)
1. Further evidence to support bimodality of oestrogen receptor expression in breast cancer.
Muftah AA; Aleskandarany M; Sonbul SN; Nolan CC; Diez Rodriguez M; Caldas C; Ellis IO; Green AR; Rakha EA
Histopathology; 2017 Feb; 70(3):456-465. PubMed ID: 27648723
[TBL] [Abstract][Full Text] [Related]
2. Estrogen Receptor-α Quantification in Breast Cancer: Concordance Between Immunohistochemical Assays and mRNA-In Situ Hybridization for ESR1 Gene.
Thomsen C; Nielsen S; Nielsen BS; Pedersen SH; Vyberg M
Appl Immunohistochem Mol Morphol; 2020; 28(5):347-353. PubMed ID: 30920963
[TBL] [Abstract][Full Text] [Related]
3. Clinicopathological characteristics of oestrogen receptor negative, progesterone receptor positive breast cancers: re-evaluating subsets within this group.
Ahmed SS; Thike AA; Zhang K; Lim JC; Tan PH
J Clin Pathol; 2017 Apr; 70(4):320-326. PubMed ID: 27612503
[TBL] [Abstract][Full Text] [Related]
4. Oncostatin M suppresses oestrogen receptor-α expression and is associated with poor outcome in human breast cancer.
West NR; Murphy LC; Watson PH
Endocr Relat Cancer; 2012 Apr; 19(2):181-95. PubMed ID: 22267707
[TBL] [Abstract][Full Text] [Related]
5. The relationship between the insulin-like growth factor-1 system and the oestrogen metabolising enzymes in breast cancer tissue and its adjacent non-cancerous tissue.
Chong YM; Colston K; Jiang WG; Sharma AK; Mokbel K
Breast Cancer Res Treat; 2006 Oct; 99(3):275-88. PubMed ID: 16752221
[TBL] [Abstract][Full Text] [Related]
6. Minimising immunohistochemical false negative ER classification using a complementary 23 gene expression signature of ER status.
Li Q; Eklund AC; Juul N; Haibe-Kains B; Workman CT; Richardson AL; Szallasi Z; Swanton C
PLoS One; 2010 Dec; 5(12):e15031. PubMed ID: 21152022
[TBL] [Abstract][Full Text] [Related]
7. Prognostic significance of androgen receptor expression in invasive breast cancer: transcriptomic and protein expression analysis.
Aleskandarany MA; Abduljabbar R; Ashankyty I; Elmouna A; Jerjees D; Ali S; Buluwela L; Diez-Rodriguez M; Caldas C; Green AR; Ellis IO; Rakha EA
Breast Cancer Res Treat; 2016 Sep; 159(2):215-27. PubMed ID: 27514395
[TBL] [Abstract][Full Text] [Related]
8. Estrogen receptor (ER) mRNA and ER-related gene expression in breast cancers that are 1% to 10% ER-positive by immunohistochemistry.
Iwamoto T; Booser D; Valero V; Murray JL; Koenig K; Esteva FJ; Ueno NT; Zhang J; Shi W; Qi Y; Matsuoka J; Yang EJ; Hortobagyi GN; Hatzis C; Symmans WF; Pusztai L
J Clin Oncol; 2012 Mar; 30(7):729-34. PubMed ID: 22291085
[TBL] [Abstract][Full Text] [Related]
9. Basal biomarkers nestin and INPP4b identify intrinsic subtypes accurately in breast cancers that are weakly positive for oestrogen receptor.
Asleh-Aburaya K; Sheffield BS; Kos Z; Won JR; Wang XQ; Gao D; Wolber R; Gilks CB; Bernard PS; Chia SK; Nielsen TO
Histopathology; 2017 Jan; 70(2):185-194. PubMed ID: 27402148
[TBL] [Abstract][Full Text] [Related]
10. Prognostic and biological significance of peroxisome proliferator-activated receptor-gamma in luminal breast cancer.
Abduljabbar R; Al-Kaabi MM; Negm OH; Jerjees D; Muftah AA; Mukherjee A; Lai CF; Buluwela L; Ali S; Tighe PJ; Green A; Ellis I; Rakha E
Breast Cancer Res Treat; 2015 Apr; 150(3):511-22. PubMed ID: 25794775
[TBL] [Abstract][Full Text] [Related]
11. Multimodal Assessment of Estrogen Receptor mRNA Profiles to Quantify Estrogen Pathway Activity in Breast Tumors.
Muthukaruppan A; Lasham A; Woad KJ; Black MA; Blenkiron C; Miller LD; Harris G; McCarthy N; Findlay MP; Shelling AN; Print CG
Clin Breast Cancer; 2017 Apr; 17(2):139-153. PubMed ID: 27756582
[TBL] [Abstract][Full Text] [Related]
12. Transcriptional implications of intragenic DNA methylation in the oestrogen receptor alpha gene in breast cancer cells and tissues.
Shenker NS; Flower KJ; Wilhelm-Benartzi CS; Dai W; Bell E; Gore E; El Bahrawy M; Weaver G; Brown R; Flanagan JM
BMC Cancer; 2015 May; 15():337. PubMed ID: 25927974
[TBL] [Abstract][Full Text] [Related]
13. Is quantitative oestrogen receptor expression useful in the evaluation of the clinical prognosis? Analysis of a homogeneous series of 797 patients with prospective determination of the ER status using simultaneous EIA and IHC.
Mazouni C; Bonnier P; Goubar A; Romain S; Martin PM
Eur J Cancer; 2010 Oct; 46(15):2716-25. PubMed ID: 20599373
[TBL] [Abstract][Full Text] [Related]
14. Androgen receptor is frequently expressed in HER2-positive, ER/PR-negative breast cancers.
Micello D; Marando A; Sahnane N; Riva C; Capella C; Sessa F
Virchows Arch; 2010 Oct; 457(4):467-76. PubMed ID: 20809337
[TBL] [Abstract][Full Text] [Related]
15. Estrogen receptor-beta expression in invasive breast cancer in relation to molecular phenotype: results from the Nurses' Health Study.
Marotti JD; Collins LC; Hu R; Tamimi RM
Mod Pathol; 2010 Feb; 23(2):197-204. PubMed ID: 19898422
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of oestrogen receptor expression in breast cancer by quantification of mRNA.
Potemski P; Pluciennik E; Bednarek AK; Kusinska R; Kubiak R; Kordek R
Histopathology; 2007 Dec; 51(6):829-36. PubMed ID: 18042072
[TBL] [Abstract][Full Text] [Related]
17. Effects of Estrogen Receptor and Human Epidermal Growth Factor Receptor-2 Levels on the Efficacy of Trastuzumab: A Secondary Analysis of the HERA Trial.
Loi S; Dafni U; Karlis D; Polydoropoulou V; Young BM; Willis S; Long B; de Azambuja E; Sotiriou C; Viale G; Rüschoff J; Piccart MJ; Dowsett M; Michiels S; Leyland-Jones B
JAMA Oncol; 2016 Aug; 2(8):1040-7. PubMed ID: 27100299
[TBL] [Abstract][Full Text] [Related]
18. Ki67 expression in invasive breast cancer: the use of tissue microarrays compared with whole tissue sections.
Muftah AA; Aleskandarany MA; Al-Kaabi MM; Sonbul SN; Diez-Rodriguez M; Nolan CC; Caldas C; Ellis IO; Rakha EA; Green AR
Breast Cancer Res Treat; 2017 Jul; 164(2):341-348. PubMed ID: 28478613
[TBL] [Abstract][Full Text] [Related]
19. Genome profiling of ERBB2-amplified breast cancers.
Sircoulomb F; Bekhouche I; Finetti P; Adélaïde J; Ben Hamida A; Bonansea J; Raynaud S; Innocenti C; Charafe-Jauffret E; Tarpin C; Ben Ayed F; Viens P; Jacquemier J; Bertucci F; Birnbaum D; Chaffanet M
BMC Cancer; 2010 Oct; 10():539. PubMed ID: 20932292
[TBL] [Abstract][Full Text] [Related]
20. Intratumoral heterogeneity as a source of discordance in breast cancer biomarker classification.
Allott EH; Geradts J; Sun X; Cohen SM; Zirpoli GR; Khoury T; Bshara W; Chen M; Sherman ME; Palmer JR; Ambrosone CB; Olshan AF; Troester MA
Breast Cancer Res; 2016 Jun; 18(1):68. PubMed ID: 27349894
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
